Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Marianne, Kjalke"'
Autor:
Brian Lauritzen, Mads Bjelke, Olle Björkdahl, Esther Bloem, Kevin Keane, Marianne Kjalke, Marie Rossen, Solvej Lund Lippert, Karin Nana Weldingh, Mikala Skydsgaard, Stine Kjellev
Publikováno v:
Journal of Thrombosis and Haemostasis. 20:1312-1324
Mim8 is a novel, next-generation factor VIIIa mimetic in development for subcutaneous prophylactic treatment of patients with hemophilia A with and without inhibitors. In vitro and in vivo models indicate that Mim8 has a distinct hemostatic potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8a297c1a3dbd1aa78cc4af6bf7161de
https://doi.org/10.1111/jth.15682
https://doi.org/10.1111/jth.15682
Publikováno v:
Haemophilia
Factor replacement therapy with factor VIII (FVIII) concentrates is the current standard of care for patients with haemophilia A. Postadministration monitoring of FVIII activity during on‐demand or prophylactic treatment is important, for example t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75e6922616a407b147e7c78282157b30
https://doi.org/10.1111/hae.13897
https://doi.org/10.1111/hae.13897
Autor:
Gert Bolt, Peter B. Johansen, Helle Heibroch Petersen, Henrik Rahbek-Nielsen, D. M. Karpf, Peder Lisby Nørby, Mette Loftager, Marianne Kjalke, Lars Thim, E. Bloem, G. E. Blouse
Publikováno v:
Journal of Thrombosis and Haemostasis. 17:350-360
Essentials Factor (F)VIII with an intermediate-length B-domain showed higher levels in murine gene therapy. FVIII with different B-domain lengths were analysed. FVIII variants with B-domains between 186 and 240 amino acids (aa) have extended half-lif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a71795725da862caf2148eb40463f37e
https://doi.org/10.1111/jth.14355
https://doi.org/10.1111/jth.14355
Publikováno v:
Journal of Thrombosis and Haemostasis
Background The anti‐tissue factor plasma inhibitor monoclonal antibody concizumab is under clinical investigation for subcutaneous prophylaxis of hemophilia A/B (HA/HB) with or without inhibitors. Breakthrough bleeds while on concizumab prophylaxis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::054cc2fa6d278f0474c6d7a0c08473e4
https://pubmed.ncbi.nlm.nih.gov/33819375
https://pubmed.ncbi.nlm.nih.gov/33819375
Autor:
Brian Lauritzen, Marie Rossen, Mads Bjelke, Olle Björkdahl, Stine Kjellev, Marianne Kjalke, Mikala Skydsgaard
Publikováno v:
Blood. 136:26-27
Introduction Mim8 is in clinical development as a novel, next generation FVIII mimetic for subcutaneous prophylactic treatment for people with Hemophilia A (HA) with and without inhibitors. Mim8 is a fully human bispecific antibody bridging FIXa and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f2f41ff5c33c5655fd75caabcab0aae
https://doi.org/10.1182/blood-2020-137006
https://doi.org/10.1182/blood-2020-137006
Autor:
Søren Andersen, Marianne Kjalke
Publikováno v:
Blood. 136:22-23
Introduction: Lack of factor VIII/IX (FVIII/FIX) in hemophilia A/B (HA/HB), respectively, results in reduced thrombin generation, leading to recurrent/spontaneous bleeds. Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e92cf9d2f5fd0b518684f3bfed5339ff
https://doi.org/10.1182/blood-2020-140272
https://doi.org/10.1182/blood-2020-140272
Autor:
Donald F. Brophy, Heidi L. Holmberg, Thomas Egebjerg, Helle Demuth, Mari Enoksson, Jens Buchardt, Thomas N. Krogh, Mette S Jensen, Marianne Kjalke, Erika J. Martin, Mads Kjelgaard-Hansen, Ida Hilden, Annika Sanfridson
Publikováno v:
Journal of thrombosis and haemostasis : JTHREFERENCES. 18(1)
Background Recombinant factor VIIa (rFVIIa) enhances thrombin generation in a platelet-dependent manner; however, rFVIIa binds activated platelets with relatively low affinity. Triggering receptor expressed on myeloid cells (TREM)-like transcript (TL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::929d68c768514bf13eb8750a838bf875
https://pubmed.ncbi.nlm.nih.gov/31549480
https://pubmed.ncbi.nlm.nih.gov/31549480
Autor:
J. Bøggild Kristensen, C. N. Gudme, Rupa S. Appa, D. M. Karpf, Gert Bolt, Carsten Behrens, Kirstine Roepstorff, Marianne Kjalke, Cristina Ionica Øie, Bård Smedsrød
Publikováno v:
Journal of Thrombosis and Haemostasis. 14:1803-1813
UNLABELLED Essentials Von Willebrand factor (VWF) stabilizes factor VIII (FVIII) and prevents its premature clearance. Rat anatomical and hepatocellular distribution studies assessed the VWF effect on FVIII clearance. Hepatocytes and liver sinusoidal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e4ad0fc0ad70df820699509a87fc2d
https://doi.org/10.1111/jth.13406
https://doi.org/10.1111/jth.13406
Publikováno v:
Journal of Thrombosis and Haemostasis. 14:1579-1587
Essentials Chromogenic assays may be less variable than one-stage clot assays for measuring modified factor VIII. Chromogenic assays were evaluated for N8-GP potency labeling and postadministration monitoring. There was no significant difference betw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9551ad3392c2e14d9580a8c2b9b66995
https://doi.org/10.1111/jth.13375
https://doi.org/10.1111/jth.13375
Autor:
Mads Kreilgaard, Peter B. Johansen, Jesper Haaning, Frederik Rode, L. F. Larsen, Mette Loftager, K. Almholt, Maj Petersen, Marianne Kjalke, D. M. Karpf, Andreas Velsing Groth
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 16(6)
Essentials N8-GP is an extended half-life recombinant factor VIII (FVIII) for the treatment of hemophilia A. Subcutaneous (SC) FVIII dosing might reduce the treatment burden of prophylaxis. SC N8-GP has a favorable PK profile in animal models and dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52535d6af3770733e2993fb3cc33722c
https://pubmed.ncbi.nlm.nih.gov/29582559
https://pubmed.ncbi.nlm.nih.gov/29582559